公开(公告)号：US12209125B2

公开(公告)日：2025-01-28

申请号：US16755082

申请日：2018-03-09

Applicant: CELLECTIS

Inventor： Brian Busser ,  Philippe Duchateau ,  Alexandre Juillerat ,  Laurent Poirot ,  Julien Valton

IPC: A61K35/00 ,  A61K39/00 ,  C07K16/28 ,  C07K16/30 ,  C12N5/0783 ,  C12N5/10

Abstract: The invention pertains to the field of adaptive cell immunotherapy. It provides with the genetic insertion of exogenous coding sequence(s) that help the immune cells to direct their immune response against infected or malignant cells. These exogenous coding sequences are more particularly inserted under the transcriptional control of endogenous gene promoters that are sensitive to immune cells activation. Such method allows the production of safer immune primary cells of higher therapeutic potential.

公开(公告)号：US11365430B2

公开(公告)日：2022-06-21

申请号：US16793918

申请日：2020-02-18

Applicant: Cellectis

Inventor： Philippe Duchateau ,  André Choulika ,  Laurent Poirot

IPC: A61K35/17 ,  C12N15/85 ,  C12N5/0783 ,  C12N9/22 ,  C12N15/90 ,  C12N15/113

Abstract: The present invention relates to methods of developing genetically engineered, preferably non-alloreactive T-cells for immunotherapy. This method involves the use of RNA-guided endonucleases, in particular Cas9/CRISPR system, to specifically target a selection of key genes in T-cells. The engineered T-cells are also intended to express chimeric antigen receptors (CAR) to redirect their immune activity towards malignant or infected cells. The invention opens the way to standard and affordable adoptive immunotherapy strategies using T-Cells for treating cancer and viral infections.

公开(公告)号：US10426795B2

公开(公告)日：2019-10-01

申请号：US14403937

申请日：2013-05-13

Applicant: Cellectis

Inventor： Roman Galetto ,  Agnes Gouble ,  Stephanie Grosse ,  Cecile Mannioui ,  Laurent Poirot ,  Andrew Scharenberg ,  Julianne Smith

IPC: C12N5/10 ,  A61K38/00 ,  A61K35/17 ,  C12N5/0783 ,  C07K14/725 ,  C07K16/28 ,  C07K14/705

Abstract: A method of expanding TCRalpha deficient T-cells by expressing pTalpha or functional variants thereof into said cells, thereby restoring a functional CD3 complex. This method is particularly useful to enhance the efficiency of immunotherapy using primary T-cells from donors. This method involves the use of pTalpha or functional variants thereof and polynucleotides encoding such polypeptides to expand TCRalpha deficient T-cells. Such engineered cells can be obtained by using specific rare-cutting endonuclease, preferably TALE-nucleases. The use of Chimeric Antigen Receptor (CAR), especially multi-chain CAR, in such engineered cells to target malignant or infected cells. The invention opens the way to standard and affordable adoptive immunotherapy strategies for treating cancer and viral infections.

公开(公告)号：US10196608B2

公开(公告)日：2019-02-05

申请号：US15120060

申请日：2015-02-20

Applicant: CELLECTIS

Inventor： Laurent Poirot ,  Philippe Duchateau

IPC: C12N9/16 ,  A61K35/17 ,  C07K14/47 ,  C07K16/28 ,  C07K14/715 ,  C07K14/725 ,  C12N5/0783

Abstract: The present invention pertains to engineered T-cells, method for their preparation and their use as medicament, particularly for immunotherapy. The engineered T-cells of the invention are designed to express both a Chimeric Antigen Receptor (CAR) directed against at least one antigen expressed at the surface of a malignant or infected cell, and a secreted inhibitor of regulatory T-cells (Treg). Preferably, such secreted inhibitor is a peptide inhibitor of forkhead/winged helix transcription factor 3 (FoxP3), a specific factor involved into the differentiation of T-cells into regulatory T-cells. The engineered T-cells of the invention direct their immune activity towards specific malignant or infected cells, while at the same time will prevent neighboring regulatory T-cells from modulating the immune response. The invention opens the way to standard and affordable adoptive immunotherapy strategies, especially for treating or preventing cancer, and bacterial or viral infections.

公开(公告)号：US12144825B2

公开(公告)日：2024-11-19

申请号：US16625678

申请日：2018-07-02

Applicant: CELLECTIS

Inventor： David Sourdive ,  Aymeric Duclert ,  Mathieu Simon ,  Philippe Duchateau ,  Alan Marc Williams ,  Laurent Poirot

IPC: A61K35/17 ,  A61K39/00 ,  C12Q1/6881

Abstract: The present invention provides composition kits and methods for treating cancer in a human by immunotherapy using successive doses of CAR-T cells with no or reduced anamnestic immune reaction in one individual (P).

公开(公告)号：US11414674B2

公开(公告)日：2022-08-16

申请号：US16361438

申请日：2019-03-22

Applicant: Cellectis

Inventor： Roman Galetto ,  Agnes Gouble ,  Stephanie Grosse ,  Cecile Mannioui ,  Laurent Poirot ,  Andrew Scharenberg ,  Julianne Smith

IPC: A61K35/17 ,  C12N15/85 ,  C07K14/705 ,  C12N5/0783 ,  C07K14/725 ,  C07K16/28 ,  A61K39/00 ,  A61K38/00

Abstract: A method of expanding deficient T-cells by expressing pTalpha or functional variants thereof into said cells, thereby restoring a functional CD3 complex. This method is particularly useful to enhance the efficiency of immunotherapy using primary T-cells from donors. This method involves the use of pTalpha or functional variants thereof and polynucleotides encoding such polypeptides to expand TCRalpha deficient T-cells. Such engineered cells can be obtained by using specific rare-cutting endonuclease, preferably TALE-nucleases. The use of Chimeric Antigen Receptor (CAR), especially multi-chain CAR, in such engineered cells to target malignant or infected cells. The invention opens the way to standard and affordable adoptive immunotherapy strategies for treating cancer and viral infections.

公开(公告)号：US10517896B2

公开(公告)日：2019-12-31

申请号：US16361370

申请日：2019-03-22

Applicant: Cellectis

Inventor： Roman Galetto ,  Agnes Gouble ,  Stephanie Grosse ,  Cecile Mannioui ,  Laurent Poirot ,  Andrew Scharenberg ,  Julianne Smith

IPC: A61K35/26 ,  A61K35/17 ,  C07K14/705 ,  C12N5/0783 ,  C07K14/725 ,  C07K16/28 ,  A61K38/00

Abstract: A method of expanding TCRalpha deficient T-cells by expressing pTalpha or functional variants thereof into said cells, thereby restoring a functional CD3 complex. This method is particularly useful to enhance the efficiency of immunotherapy using primary T-cells from donors. This method involves the use of pTalpha or functional variants thereof and polynucleotides encoding such polypeptides to expand TCRalpha deficient T-cells. Such engineered cells can be obtained by using specific rare-cutting endonuclease, preferably TALE-nucleases. The use of Chimeric Antigen Receptor (CAR), especially multi-chain CAR, in such engineered cells to target malignant or infected cells. The invention opens the way to standard and affordable adoptive immunotherapy strategies for treating cancer and viral infections.

公开(公告)号：US10472613B2

公开(公告)日：2019-11-12

申请号：US15517708

申请日：2015-10-07

Applicant: CELLECTIS

Inventor： Philippe Duchateau ,  Alexandre Juillerat ,  Laurent Poirot

IPC: C07K14/705 ,  C12N5/16 ,  C07K14/725 ,  C12N5/078 ,  C12N5/0783 ,  C12N5/10 ,  C12N5/07 ,  C12N15/02 ,  C12N15/87

Abstract: The present invention relates to a method to modulate the level of activation of an engineered immune cell (such as a Chimeric Antigen Receptor T-cell) for immunotherapy. The present invention also relates to cells obtained by the present method, preferably comprising said modulable/tunable chimeric antigen receptors for use in therapeutic or prophylactic treatment.

公开(公告)号：US20170067022A1

公开(公告)日：2017-03-09

申请号：US15120060

申请日：2015-02-20

Applicant: CELLECTIS

Inventor： Laurent Poirot ,  Philippe Duchateau

IPC: C12N5/0783 ,  A61K35/17 ,  C07K16/28 ,  C07K14/47 ,  C07K14/725 ,  C07K14/715

CPC classification number: C12N5/0638 ,  A61K35/17 ,  C07K14/4703 ,  C07K14/7051 ,  C07K14/7155 ,  C07K16/2803 ,  C07K16/2866 ,  C07K2317/622 ,  C07K2319/74 ,  C12N5/0636 ,  C12N9/16 ,  C12N2501/60 ,  C12N2510/00

Abstract: The present invention pertains to engineered T-cells, method for their preparation and their use as medicament, particularly for immunotherapy. The engineered T-cells of the invention are designed to express both a Chimeric Antigen Receptor (CAR) directed against at least one antigen expressed at the surface of a malignant or infected cell, and a secreted inhibitor of regulatory T-cells (Treg). Preferably, such secreted inhibitor is a peptide inhibitor of forkhead/winged helix transcription factor 3 (FoxP3), a specific factor involved into the differentiation of T-cells into regulatory T-cells. The engineered T-cells of the invention direct their immune activity towards specific malignant or infected cells, while at the same time will prevent neighbouring regulatory T-cells from modulating the immune response. The invention opens the way to standard and affordable adoptive immunotherapy strategies, especially for treating or preventing cancer, and bacterial or viral infections.

Abstract translation: 本发明涉及工程化T细胞，其制备方法及其作为药物的用途，特别是用于免疫治疗。 本发明的工程化T细胞被设计为表达针对在恶性或感染细胞表面表达的至少一种抗原的嵌合抗原受体（CAR）和调节性T细胞（Treg）的分泌抑制剂。 优选地，这种分泌的抑制剂是叉头/翼状螺旋转录因子3（FoxP3）的肽抑制剂，其涉及T细胞分化成调节性T细胞的特异性因子。 本发明的工程化T细胞将其免疫活性指向特定的恶性或感染细胞，同时将阻止相邻的调节性T细胞调节免疫应答。 本发明开启了标准和负担得起的过继性免疫治疗策略的方式，特别是治疗或预防癌症以及细菌或病毒感染。

公开(公告)号：US11903968B2

公开(公告)日：2024-02-20

申请号：US16629506

申请日：2018-07-20

Applicant: CELLECTIS

Inventor： Philippe Duchateau ,  Anne-Sophie Gautron ,  Laurent Poirot ,  Julien Valton

IPC: C12N5/00 ,  A61K35/17 ,  A61K39/395 ,  C07K16/28 ,  C12N5/0783 ,  C12N15/113

CPC classification number: A61K35/17 ,  A61K39/39541 ,  C07K16/2818 ,  C12N5/0636 ,  C12N15/113 ,  C12N2310/14 ,  C12N2510/00

Abstract: The invention pertains to the field of adoptive cell immunotherapy. It provides with engineered immune cells comprising genetic alteration into genes which are involved into immune functions downregulation, especially in response to environment signals such as nutrients depletion. Such method allows the production of more potent immune cells in the context of tumors' microenvironment.